Janssen Pharmaceuticals Acquire GSK Antiviral

Johnson & Johnson’s Janssen Pharmaceuticals has acquired an investigational antiviral from GlaxoSmithKline (GSK) with the aim to develop an oral regimen for the treatment of hepatitis C (HCV). The pharmaceutical company has paid to obtain access to the NS5a replication complex inhibitor GSK2336805, which GlaxoSmithKline and their partner, Vertex, had taken up to clinical Phase

Continue Reading

AbbVie and Galapagos Sign $405 Million Agreement

After recently signing an anti-inflammatory deal with Ablynx, AbbVie has now announced a new agreement with Galapagos in cystic fibrosis. Specifically, the organisations have confirmed that they will contribute technologies and resources to develop oral drugs that address the main mutations in cystic fibrosis patients, including F508del and G551D, with the intention of starting Phase

Continue Reading

Physicians 2 Pharma Workshop

Only Medics will be hosting a day of workshops for medics looking to transition to the pharmaceutical industry. The workshop will take place on Thursday 26th September in Reading, UK.  Attendance to the workshop is by invitation only. In addition to medics, the workshop will be attended by industry physicians and HR professionals, some of whom are actively

Continue Reading

AstraZeneca Partners with Merck & Co

AstraZeneca have announced that they have licensed a drug which is currently in mid-stage clinical studies for ovarian cancer from Merck & Co. The agreement revolves around MK-1775, an oral small molecule inhibitor of WEE1 kinase, a cell cycle checkpoint protein regulator. Preclinical results have indicated that disruption of WEE1 may improve the cell killing

Continue Reading

Otsuka Pharmaceutical to Acquire Astex

Japan’s Otsuka has agreed to purchase cancer specialist, Astex Pharmaceuticals, in a deal which is valued at $886 million. Otsuka will obtain the remaining shares of Astex for $8.50 per share in cash, signifying a 48% premium to the average closing stock price for the prior 30-day period. One of the main reasons behind the

Continue Reading

Incyte Shares Jump, After Positive Phase II Results for Jakafi

Shares in Incyte increased by almost 34% yesterday after the company announced promising mid-stage data for their pancreatic cancer therapy, Jakafi. Positive results from a Phase II clinical trial showed that the JAK inhibitor, Jakafi (ruxolitinib), when used in combination with Roche’s Xeloda (capecitabine), improved survival in some patients with recurrent or treatment refractory advanced

Continue Reading

Amgen Finalises Agreement With Servier

Amgen have confirmed a new partnership with Servier to boost the pipelines of both businesses. The waiting period to let any antitrust concerns to arise has now passed, meaning the two companies can advance with the agreement. The deal will provide Amgen with rights in the US to Servier’s heart drug, ivabradine, which has already

Continue Reading

Novo Nordisk Post Strong Q2 Results

Novo Nordisk has announced another strong set of results, aided by strong sales of their diabetes drug, Victoza. The company’s net profit for the second quarter increased by 26% to 6.73 billion Danish kroner (equal to roughly $1.20 billion), while sales grew 10% to 21.38 billion kroner. The organisation’s group of modern insulin products, including

Continue Reading